Evaxion Biotech to present data from Phase 2 trial of EVX-01

Evaxion will present a wide range of data from its phase 2 trial with lead compound EVX-01 at the European Society for Medical Oncology Congress 2025 to be held in Berlin, Germany, from October 17-21, 2025. The data, which will be presented at an oral session, will include two-year clinical efficacy, immunogenicity and safety data. More specifically, data will be presented on best overall response, deepened response/conversion rates and durability of response. Furthermore, the presentation will include data on the breadth, magnitude and duration of T-cell response upon booster immunization as well as data on the vaccine’s safety profile. Designed with Evaxion’s AI-Immunology platform, EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma. The trial has yielded numerous convincing data already, including interim one-year data presented at the ESMO Congress last year. Data demonstrated a 69% Overall Response Rate, reduction in tumor target lesions in 15 out of 16 patients, and a positive correlation between the AI-Immunology platform predictions and immune responses induced by the individual neoantigens in the EVX-01 vaccine. Further, the most recent immune data demonstrates that 80% of EVX-01 vaccine targets triggered a tumor-specific immune response.